ELAVL1 and Patent ductus arteriosus: In order to better understand the mechanism by which HuR inhibition affects PDA phenotype in preclinical models, we performed gene expression analyses using the nCounter® GX Human Cancer Reference Kit (NanoString Technologies, Seattle, WA), which allows for high-sensitivity and high-precision profiling of 230 genes (plus 6 housekeeping genes) known to be differentially expressed in various human cancers (see Table S1 for the full list of genes in the panel) [59].